MetaCap

MIRA Pharmaceuticals (MIRA) vs Tvardi Therapeutics (TVRD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tvardi Therapeutics (TVRD) has outperformed MIRA Pharmaceuticals (MIRA) over the past year, losing 74.8% versus a loss of 79.1%. Tvardi Therapeutics is the larger company by market cap ($13.2 million vs $12.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIRA-79.06%TVRD-74.76%
+33%-26%-85%
Nov 21, 20251 yearNov 20, 2026
MIRA-95.16%TVRD-99.12%
+19%-43%-105%
Jul 31, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIRA versus TVRD key metrics
MetricMIRATVRD
Share price$0.291$0.9893
Market cap$12.23M$13.22M
1-day change-20.84%+4.57%
YTD return-80.73%-76.99%
1-year return-79.06%-74.76%
5-year return—-99.79%
P/E ratio (TTM)29.10—
EPS (TTM)$0.01$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-10.44M$-18.21M
52-week high$1.69$5.69
52-week low$0.255$0.773
Distance from 52-week high-82.78%-82.61%
Analyst consensusnonebuy
Avg. price target upside+1102.75%+835.00%
Average volume622.02K235.95K
Shares outstanding42.02M13.36M
Employees—12
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MIRA Pharmaceuticals

MIRA stock →

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.

Health Care · Biotechnology: Pharmaceutical Preparations

About Tvardi Therapeutics

TVRD stock →

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

MIRA vs TVRD FAQ

Which is bigger, MIRA Pharmaceuticals or Tvardi Therapeutics?

Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $13.22M compared with $12.23M for MIRA Pharmaceuticals (MIRA).

Which stock has performed better over the past year, MIRA or TVRD?

TVRD returned -74.76% over the past 12 months, compared with -79.06% for MIRA (price return, excluding dividends). Past performance does not predict future results.

Are MIRA Pharmaceuticals and Tvardi Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons